Exhibit 99.1 Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates -- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 CGD in 2025-- phox -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in 1H 2026 – -- Additional high-value programs advancing through preclinical development-- Cambridge, Mass., February 28, 2025 – Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a ne ...

-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or CTA in 1H 2026 -- -- Additional high-value programs advancing through preclinical development -- CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported fina ...

CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, MA. A live audio webcast of the presentation will be available ...

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prime Medicine, Inc. (NASDAQ: PRME) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you are a long-term PRME stockholder please contact Justin Kuehn, Esq. here, by email at [email protected], or call (833) 672-0814. The consultation ...

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA. A live audio webcast of the present ...

Prime Medicine, Inc. (NASDAQ: PRME ) is working on leading gene-editing technology, leveraging its proprietary Prime Editing platform. This IP offers one-time therapeutic solutions for conditions with limited or no treatment alternatives. The company’s pipeline includes its leading candidate, PM359, indicated for chronic granulomatousMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree ...

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Wilson Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Wilson Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactiv ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission file number 001-41536 Prime Medicine, Inc. (Exact name of registrant as specified in its charter) De ...

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates -- Presented initial in vivo data for universal liver-targeted LNP and Wilson's Disease program at ESGCT; initiated IND-enabling activities for Wilson's Disease program in 4Q 2024 and remains on track to file IND and/or CTA in 1H 2026 -- -- Announced strategic research collaboration and license agreement with Bristol Myers Squibb; received $110 million upfront, with potential for more than $3.5 billion in milestone pay ...

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Guggenheim's Inaugural Healthcare Innovation Conference: Fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.Stifel 2024 Healthcare Conference: Fireside chat on Monday, November 18, 2024, ...